This week, 5 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Slipping from a C to a D rating, RedHill Biopharma Ltd. Sponsored ADR (RDHL) takes a hit this week. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RDHL stock.
Cardiome Pharma Corp. (CRME) slips from a D to a F this week. Cardiome Pharma Corp. focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRME stock.
This week, Imprimis Pharmaceuticals, Inc.’s (IMMY) rating worsens to a D from the company’s C rating a week ago. Imprimis Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of non-invasive topically delivered medications. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMY stock.
BioDelivery Sciences International, Inc. (BDSI) experiences a ratings drop this week, going from last week’s D to a F. BioDelivery Sciences International, Inc. is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BDSI stock.
Pulmatrix Inc (PULM) is having a tough week. The company’s rating falls from a D to a F. For more information, get Portfolio Grader’s complete analysis of PULM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
